Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic

Krasselt, Marco; Baerwald, Christoph; Seifert, Olga

doi:10.1007/s00393-017-0410-5

Cited by 22 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the screening of the title and/or abstract, 8,850 items were discarded. The fulltext of 60 investigations was assessed and 14 texts were excluded with reasons (as reported in Table 2) (21,26,27,(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40). Finally, 22 articles were included (4 studies had overlapping populations) in the present systematic reviews.…”

Section: Resultsmentioning

confidence: 99%

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Adawi

Bragazzi

McGonagle

et al. 2019

Autoimmunity Reviews

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Adawi

Bragazzi

McGonagle

et al. 2019

Autoimmunity Reviews

View full text Add to dashboard Cite

show abstract

“…Streptococcus pneumoniae, Influenza) are low among patients with inflammatory rheumatic diseases and immunosuppression in general. [17][18][19] Contrary to patients with Rheumatoid Arthritis, 20 investigations on vasculitis and intensive care treatment for sepsis are scarce or address ICU treatment in general without focusing on sepsis in particular. [4][5][6][7][8]10,[21][22][23][24] We therefore planned to investigate retrospectively the outcome of sepsis in necrotizing vasculitis patients requiring intensive care treatment in a university hospital in Germany.…”

Section: Introductionmentioning

confidence: 99%

Outcome of Patients With Necrotizing Vasculitis Admitted to the Intensive Care Unit (ICU) for Sepsis: Results of a Single-Centre Retrospective Analysis

Krasselt

Baerwald

Petros

et al. 2020

J Intensive Care Med

View full text Add to dashboard Cite

Introduction/Background: Vasculitis patients have a high risk for infections that may require intensive care unit (ICU) treatment in case of resulting sepsis. Since data on sepsis mortality in this patient group is limited, the present study investigated the clinical characteristics and outcomes of vasculitis patients admitted to the ICU for sepsis. Methods: The medical records of all necrotizing vasculitis patients admitted to the ICU of a tertiary hospital for sepsis in a 13-year period have been reviewed. Mortality was calculated and multivariate logistic regression was used to determine independent risk factors for sepsis mortality. Moreover, the predictive power of common ICU scores was further evaluated. Results: The study included 34 patients with necrotizing vasculitis (mean age 69 ± 9.9 years, 35.3% females). 47.1% (n = 16) were treated with immunosuppressives (mostly cyclophosphamide, n = 35.3%) and 76.5% (n = 26) received glucocorticoids. Rituximab was used in 4 patients (11.8%).The in-hospital mortality of septic vasculitis patients was 41.2%. The Sequential Organ Failure Assessment (SOFA) score (p = 0.003) was independently associated with mortality in multivariate logistic regression. Acute Physiology And Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II) and SOFA scores were good predictors of sepsis mortality in the investigated vasculitis patients (APACHE II AUC 0.73, p = 0.02; SAPS II AUC 0.81, p < 0.01; SOFA AUC 0.898, p < 0.0001). Conclusions: Sepsis mortality was high in vasculitis patients. SOFA was independently associated with mortality in a logistic regression model. SOFA and other well-established ICU scores were good mortality predictors.

show abstract

“…При этом вопрос безопасности вакцинации у больных РЗ, в первую очередь в плане возможного обострения аутоиммунного заболевания, до настоящего времени возникает у многих ревматологов. Отсутствие рекомендаций со стороны лечащих врачей, а также низкая информированность самих больных о возможности и необходимости иммунизации являются причиной низкого охвата вакцинацией пациентов с РЗ [14][15][16][17][18].…”

Section: Discussionunclassified

Investigation of Immunogenicity and Safety of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients With Systemic Lupus Erythematosus

Тарасова¹,

Белов²,

Буханова³

et al. 2018

rsp

View full text Add to dashboard Cite

Objective: to investigate the safety and immunogenicity of 23-valent polysaccharide pneumococcal vaccine (PPV-23) in patients with systemic lupus erythematosus (SLE). Subjects and methods. The investigation enrolled 30 patients with a reliable diagnosis of SLE; of them there were 27 women and 3 men at the age of 19 to 62 years. The disease duration ranged from 9 months to 20 years. At the time of inclusion in the investigation, the disease activity was high in 2 patients, moderate in 3, and low in 20; five patients were in remission. During a year before vaccination, pneumonia was detected in 5 (16.7%) of the 30 patients; there were a total of 18 episodes of various respiratory and ENT infections. The patients were examined at baseline and at 1, 3 and 12 months after vaccination. Standard clinical and laboratory studies and a detailed blood immunological analysis were carried out at visits. The levels of IgG antibodies to capsular polysaccharide pneumococcus were determined during each visit. Twenty-nine patients received glucocorticoids (GCs) at a dose of 5–30 mg/day; 24 – hydroxychloroquine; 14 – cytostatics (CS); 10 – biological agents (BAs) (5 – rituximab, 5 – belimumab). A single dose of 0.5 ml of PPV-23 (Pneumo 23, Aventis) was subcutaneously injected into the upper outer arm. Vaccination was done during the ongoing therapy with GC/CS and belimumab, as well as at least 1 month before the first (next) administration and/or 4.5–5 months after the last rituximab infusion. Results and discussion. 60% of patients were observed to have mild and moderate standard local vaccine reactions; 1 (3.3%) patient had a local hyperergic reaction eliminated within 7 days of the local application of antihistamines and GCs. During the follow-up, there was no SLE exacerbation significantly associated with the vaccination performed. No new autoimmune phenomena were found in any of the cases. A year after vaccination, a significant (2-fold or more) increase in anti-pneumococcal antibody levels remained in 19 (63.3%) patients (respondents); 36.7% of patients were nonrespondents. Among the patients who received a BA, the non-responders were significantly more than among those who did not take the drug (7 (70%) and 4 (20%), respectively) (p = 0.01). When treated with rituximab and belimumab, the number of non-respondents was comparable (4 and 3, respectively). The immunogenicity of PPV-23 was independent of the degree of SLE activity: the vaccine response was absent in 1 out of the 5 patients with high (n = 2) and medium (n = 3) SLE activities, as well as in 10 out of the 25 patients with low disease activity and remission. There was no development of considerable adverse reactions after vaccination in patients with high and medium SLE activity. The overall clinical efficiency of vaccination was 93.3%. Conclusion. Thus, PPV-23 shows a good tolerability and a sufficient immunogenicity in patients with SLE. There is a need for further investigations conducted in large samples of patients during long-term follow-ups in order to more fully evaluate the clinical efficacy, tolerability, and immunogenicity of PPV-23.

show abstract

Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic

Abstract: Vaccination rates have to be improved among SLE patients, in particular for vaccines protecting from respiratory tract infections such as pneumococcus and influenza.

Cited by 22 publications

References 43 publications

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Outcome of Patients With Necrotizing Vasculitis Admitted to the Intensive Care Unit (ICU) for Sepsis: Results of a Single-Centre Retrospective Analysis

Investigation of Immunogenicity and Safety of 23-Valent Polysaccharide Pneumococcal Vaccine in Patients With Systemic Lupus Erythematosus

Contact Info

Product

Resources

About